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791Enhanced Mortality Risk Prediction With a Focus on
High-Risk Percutaneous Coronary InterventionObjectives This study sought to update and validate a contemporary model for inpatient mortality following percutaneous
coronary intervention (PCI), including variables indicating high clinical risk.
Background Recently, new variables were added to the CathPCI Registry data collection form. This modiﬁcation allowed us to
better characterize the risk of death, including recent cardiac arrest and duration of cardiogenic shock.
Methods Data from 1,208,137 PCI procedures performed between July 2009 and June 2011 at 1,252 CathPCI Registry sites were
used to develop both a “full” and pre-catheterization PCI in-hospital mortality risk model using logistic regression. To support
prospective implementation, a simpliﬁed bedside risk score was derived from the pre-catheterization risk model. Model
performance was assessed by discrimination and calibration metrics in a separate split sample.
Results In-hospital mortality was 1.4%, ranging from 0.2% among elective cases (45.1% of total cases) to 65.9% among patients
with shock and recent cardiac arrest (0.2% of total cases). Cardiogenic shock and procedure urgency were the most predictive of
inpatient mortality, whereas the presence of a chronic total occlusion, subacute stent thrombosis, and left main lesion location were
signiﬁcant angiographic predictors. The full, pre-catheterization, and bedside risk prediction models performed well in the overall
validation sample (C-indexes 0.930, 0.928, 0.925, respectively) and among pre-speciﬁed patient subgroups. The model was well
calibrated across the risk spectrum, although slightly overestimating risk in the highest risk patients.
Conclusions Clinical acuity is a strong predictor of PCI procedural mortality. With inclusion of variables that further characterize
clinical stability, the updated CathPCI Registry mortality models remain well-calibrated across the spectrum of PCI risk. (J Am Coll
Cardiol Intv 2013;6:790–9) ª 2013 by the American College of Cardiology FoundationThe CathPCI Registry mortality risk prediction models
were developed to standardize assessment of percutaneous
coronary intervention (PCI) outcomes in a discipline where
patient characteristics are associated with more than a 100-
fold variation in expected mortality (1,2). These models have
multiple clinical applications, including use for patient and
family counseling (3) and serving as a foundation for quality
assessment and improvement initiatives (4,5). To satisfy
these various applications, 3 mortality risk models have been
previously developed, including a “full” model with angio-
graphic details, a pre-catheterization model, and a simpliﬁed
bedside risk score (2). Although each of these models has
unique strengths, all 3 have been shown to have excellent
performance in contemporary clinical practice (2).
Whereas the existing CathPCI Registry mortality models
have many assets, they have been criticized for failing to
accurately deﬁne risk among “extreme risk” patients (6), such
as those with cardiogenic shock and those who have suffered
cardiac arrest prior to PCI. This criticism has led to concerns
about whether decision makers will adopt risk-averse patternsHealth Care System, Newark, Delaware. This research was supported by the American College
expressed in this manuscript represent those of the author(s), and do not necessarily represent
ncdr.com. Dr. Curtis has received salary support from the American College of Cardiolog
Dr. Khandelwal has received consulting fees from TerumoMedical Corp. Dr. Spertus has rece
of NCDR data. Dr. Weaver has served on the Data and Safety Monitoring Board of Bost
Boehringer Ingelheim, Pﬁzer, and Eli Lilly. All other authors have reported that they have n
Manuscript received July 24, 2012; revised manuscript received March 12, 2013, acceptedof patient care, especially as public outcome reporting and
payment incentives for procedural outcomes are becoming
increasingly common (7,8).
In response to these concerns, and to further deﬁne risk at
the highest end of the spectrum, a series of new variables were
included in the 2009 updated Version 4 CathPCI Registry
data clariﬁcation form (DCF v4). These variables have
recently been incorporated into the CathPCI Registry risk
adjustment model that is currently used for site-level outcome
reporting. In this analysis, we sought to: 1) assess the asso-
ciation between clinical instability and in-hospital mortality
following PCI in contemporary practice; and 2) evaluate the
performance of the updated CathPCI Registry DCF v4
mortality models across the spectrum of procedural risk.
Methods
The CathPCI Registry is an initiative of the American
College of Cardiology Foundation and the Society for
Cardiovascular Angiography and Interventions. Details ofof Cardiology Foundation’s National Cardiovascular Data Registry (NCDR). The views
the ofﬁcial views of the NCDR or its associated professional societies identiﬁed at www.
y and Centers for Medicare & Medicaid Services; he also owns stock in Medtronic.
ived consulting fees from the American College of Cardiology Foundation for the analysis
on Scientiﬁc. Dr. Peterson has received consulting fees from Janssen Pharmaceuticals,
o relationships relevant to the contents of this paper to disclose.
March 15, 2013.
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792the registry and the development of its mortality risk
prediction models have been reported previously (2). In the
present analysis, patients were included if they underwent
a PCI procedure at any of the 1,253 participating centers
contributing data to the CathPCI Registry using DCF v4
between July 1, 2009, and June 30, 2011. Patients were
excluded if they were transferred to another acute care center
from the center performing the index procedure (8,619
patients were excluded, including all patients at 1 center).
Only the ﬁrst PCI procedure per admission was included.
The resulting cohort was randomly allocated to either
a model development (60%) or a model validation (40%)
sample, with stratiﬁcation according to the presence of ST-
segment elevation myocardial infarction (STEMI) to ensure
appropriate distribution of these high-risk patients. As the
primary analytic center for the CathPCI Registry, the Duke
Clinical Research Institute performed the analyses forAbbreviations
and Acronyms
BMI = body mass index
CI = conﬁdence interval
DCF v4 = Version 4 CathPCI
Registry data clariﬁcation
form
EF = ejection fraction
GFR = glomerular ﬁltration
rate
IQR = interquartile range
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarctionthis risk prediction model, had
complete access to the data, and
vouches for its integrity.
Variable deﬁnitions. Beginning
in July 2009, several updated and
new variables were incorporated
into the CathPCI Registry DCF
v4, including those describing
cardiogenic shock and cardiac
arrest. In DCF v4, “cardiogenic
shock” was redeﬁned using a sys-
tolic blood pressure <90 mm Hg
and/or cardiac index <2.2 l/
min/m2 (vs. systolic blood pres-
sure <80 mm Hg and/or cardiac
index <1.8 l/min/m2 in DCF
v3), and it was further classiﬁed
as occurring within 24 h or at the
start of the PCI procedure (vs. atany time since hospital admission in DCF v3). “Cardiac
arrest,” a new variable in DCF v4, included pulseless clinical
scenarios requiring cardiopulmonary resuscitation within
24 h of the PCI procedure. The deﬁnitions for other data
elements are available on the NCDR (National Cardiovas-
cular Data Registry) website (9).
To delineate pre-procedural clinical instability, a composite
variable including cardiogenic shock and procedural status
was developed for use in the DCF v4 mortality models, with
the following 6 ordinal categories describing decreasing levels
of procedural urgency: 1) sustained shock (occurring within
24 h and at the start of PCI) and salvage; 2) sustained shock
alone or salvage alone; 3) transient shock (occurring within 24
h or at the start of PCI, but not both) without salvage; 4)
emergent PCI without shock; 5) urgent PCI without shock;
and 6) elective PCI.
Missing data. In this cohort, missing data were rare (<5%)
for all variables except glomerular ﬁltration rate (GFR) (8%)and ejection fraction (EF) (29%) and were imputed as
follows: 1) for variables pertaining to past medical history,
pre-procedural intra-aortic balloon pump, presence of sub-
acute stent thrombosis, and “highest risk” coronary lesion,
missing data were imputed to “no”; 2) for body mass index
(BMI), missing values were imputed to the sex-speciﬁc
median; 3) for GFR, missing values were imputed to the
sex-, prior renal failure-, and STEMI-speciﬁc median; and 4)
for EF, missing data were imputed to the strata-speciﬁc
median based on a history of congestive heart failure, prior
myocardial infarction, pre-procedural cardiogenic shock, and
the presence of STEMI. These imputation rules have been
previously shown to yield results similar to those using
multiple imputation methods (2).
Statistical analysis. Potential candidate variables were
screened using both clinical judgment and knowledge gained
from previous mortality models. Following a review of the
univariate association between potential variables and in-
hospital mortality, a multivariate logistic regression with
backward selection was performed to identify variables for
the ﬁnal model (p < 0.05 for model inclusion). Spline
functions were evaluated for all continuous covariates and
were used in the modeling of EF (60%), BMI (30 kg/m2),
age (70 years), and GFR (30 and 90 ml/min/1.73 m2).
As with the previous CathPCI Registry model develop-
ment efforts, 3 models were developed, including: 1) a “full”
model with all selected candidate variables; 2) a “pre-cath”
model excluding angiographic data; and 3) a “limited” pre-
cath risk prediction model including only variables with the
strongest impact on the full model, based onWald chi-square
values. The full risk prediction model is currently used for
institutional reporting of risk-adjusted outcomes, whereas the
pre-cath and limited models have been developed to facilitate
personalized patient consent and bedside risk approximation.
Regression coefﬁcients from the pre-cath model were con-
verted to whole integers to create the simpliﬁed (“limited”)
CathPCI Registry mortality risk prediction score (10). SAS
statistical software (version 9.2, SAS Institute, Cary, North
Carolina) was used for all calculations.
Comparison of old (v3 DCF) versus updated (v4 DCF) risk-
adjustment models. The risk adjustment models presented
here (v4 DCF) have important differences when compared
with previously published models (v3 DCF). For each of the
updated (v4 DCF) models, consistent variables have been
recalibrated to ﬁt the most contemporary data. Compared
with the previous (v3 DCF) full model, the updated (v4
DCF) full model has substituted the “pre-procedural clinical
stability” variables for those that previously described “PCI
status.” Additionally, the new model version does not
include stratiﬁcation by “STEMI status” (STEMI vs. no
STEMI) for GFR, BMI, lesion risk, or New York Heart
Association class. Finally, indicators for recent cardiac arrest
(<24 h), number of diseased vessels, and chronic total
occlusions have been added to the updated (v4 DCF)
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793models that are presented here. These changes have also
been carried over to the pre-cath model.
For the simpliﬁed “bedside risk scoring system,” PCI
status has been replaced with the composite “pre-procedural
clinical stability” and the “cardiac arrest <24 h” variables
(without stratiﬁcation for STEMI status). Additionally,
BMI, prior PCI, diabetes, and left ventricular ejection
fraction have all been added to the simpliﬁed model.
Model performance. Following development, each of the
3 models was applied to the validation sample. Model dis-
crimination was assessed using a C-index, and model cali-
bration was assessed by rank-ordering patients from lowest
to highest predicted risk and comparing predicted versus
observed event rates within risk strata. Although the
Hosmer-Lemeshow goodness-of-ﬁt test was expected to be
signiﬁcant in a sample of this size, results were provided forFigure 1. Population Flow Diagram
Between July 1, 2009, and June 30, 2011, 1,249,547 PCI lab visits of 1,216,756 PCI ad
1,208,137 total patients were included in the overall model development and valida
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.reference. Calibration and discrimination were further as-
sessed within several important patient subgroups, including
according to sex, age (70 years, >70 years), and presence of
diabetes mellitus and STEMI. This model validation was
performed as a part of the v4 model development process and
is reported here to further qualify the validity of the current
risk-adjustment model in contemporary practice.
Results
Between July 2009 and June 2011, 1,249,547 PCI proce-
dures were performed at 1,253 participating CathPCI
Registry sites (Fig. 1). Following exclusions, 1,208,137
procedures from 1,252 sites remained, with an average age
of 65 years and including 33% women, 36% with diabetes,
and 40% with a prior PCI (Table 1). Pre-procedural andmissions were recorded in the NCDR CathPCI Registry. Following exclusions,
tion cohort. NCDR ¼ National Cardiovascular Data Registry; PCI ¼ percutaneous
Table 1. Patient Clinical Characteristics
Development
(n ¼ 724,883)
Validation
(n ¼ 483,254)
Patient characteristics
Age, yrs 65.0 (56.0–74.0) 65.0 (56.0–74.0)
70 66.9 67.0
>70 33.1 33.0
Female 32.7 32.6
Caucasian 88.4 88.4
BMI, kg/m2 29.1 (25.7–33.3) 29.1 (25.7–33.3)
30 56.6 56.6
>30 43.4 43.4
Prior MI 29.7 29.8
Prior CHF 11.6 11.6
Diabetes mellitus
Noninsulin 23.1 22.9
Insulin 13.0 13.0
GFR, MDRD 74.4 (58.3–90.6) 74.4 (58.3–90.6)
Dialysis 2.3 2.3
CVD 12.1 12.2
PAD 12.4 12.4
Chronic lung disease 15.0 15.0
Prior PCI 40.4 40.5
NYHA class within 2 weeks
IV 3.9 3.9
I/II/III 5.7 5.6
No CHF 90.4 90.5
LVEF 55.0 (45.0–60.0) 55.0 (45.0–60.0)
Clinical presentation
Cardiogenic shock
Within 24 h 1.8 1.8
At start of PCI 2.1 2.1
PCI status
Elective 45.3 45.3
Urgent 37.4 37.4
Emergent 17.0 17.0
Salvage 0.3 0.3
Cardiogenic shock and PCI status
Sustained shock and salvage 0.2 0.2
Sustained shock or salvage 1.2 1.3
Transient shock but not salvage 1.2 1.2
Emergency PCI without
shock/salvage
15.3 15.3
Urgent PCI without shock/salvage 37.0 37.0
Elective PCI without shock/salvage 45.1 45.1
Cardiac arrest within 24 h 1.8 1.8
Procedural characteristics
Highest risk coronary segment treated
Proximal LAD 14.9 14.9
Left main 1.7 1.7
TIMI ﬂow grade 0 17.6 17.6
Mechanical ventricular support 0.4 0.3
Continued in the next column
Table 1. Continued
Development
(n ¼ 724,883)
Validation
(n ¼ 483,254)
Subacute stent thrombosis 0.3 0.3
Number of diseased vessels
0 or 1 59.7 59.6
2 or 3 40.3 40.4
Chronic total occlusion treated 3.0 3.0
Hospital characteristics
Number of beds 409 (279–570) 409 (279–571)
Annual PCI volume 721 (444–1,167) 721 (444–1,167)
Values are % or median (interquartile range).
BMI ¼ body mass index; CHF ¼ congestive heart failure; CVD ¼ cerebrovascular disease;
GFR ¼ glomerular ﬁltration rate; LAD ¼ left anterior descending; LVEF¼ left ventricular ejection
fraction; MDRD ¼ Modiﬁcation of Diet in Renal Disease; MI ¼ myocardial infarction; NYHA ¼
New York Heart Association; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary
intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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794angiographic characteristics were well balanced across the
cohorts used for mortality model development (n ¼ 724,883)
and validation (n ¼ 483,254).
Pre-procedural clinical instability in contemporary practice.
In total, 660,851 procedures (57%) were performed in
nonelective clinical scenarios, including 37.4% urgent, 17.0%
emergent, and 0.3% salvage cases. Percutaneous coronary
intervention was performed within 24 h of a cardiac arrest in
1.8% (n¼ 21,746) of patients. Cardiogenic shock and salvage
status were both relatively rare within 24 h prior to the PCI
procedure, and the distribution of these high-risk indicatorsTable 2. Unadjusted In-Hospital Mortality
Development
(n ¼ 724,883)
Validation
(n ¼ 483,254)
Overall population 1.38 1.40
MI status
STEMI 5.22 5.33
No STEMI 0.65 0.65
Men 1.22 1.23
Women 1.72 1.74
Age group
Age >70 yrs 2.23 2.25
Age 70 yrs 0.96 0.98
Diabetes status
Diabetes mellitus 1.51 1.50
No diabetes mellitus 1.31 1.34
Cardiac arrest 24.32 25.07
Cardiogenic shock and PCI status
Sustained shock and salvage 63.99 68.85
Sustained shock or salvage 33.45 34.33
Transient shock but not salvage 15.26 14.85
Emergency PCI without shock/salvage 2.26 2.29
Urgent PCI without shock/salvage 0.63 0.63
Elective PCI without shock/salvage 0.18 0.18
Values are %.
STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Table 1.
Table 3. Full and Pre-Cath NCDR CathPCI Registry In-Hospital Mortality Risk Prediction Models
Full Model Pre-Cath Model
OR 95% CI Chi-Square OR 95% CI Chi-Square
Intercept 873.59 796.27
STEMI patients 1.87 1.75–2.00 327.44 1.80 1.68–1.93 295.95
Age*
70 yrs 1.35 1.30–1.40 253.97 1.37 1.32–1.42 291.68
>70 yrs 1.71 1.64–1.78 612.70 1.74 1.67–1.81 654.44
BMIy
30 kg/m2 0.81 0.78–0.84 121.86 0.82 0.79–0.85 113.87
>30 kg/m2 1.14 1.10–1.17 79.77 1.13 1.10–1.16 70.93
CVD 1.13 1.06–1.21 14.48 1.15 1.08–1.23 18.81
PAD 1.27 1.19–1.36 53.78 1.33 1.25–1.42 76.08
Chronic lung disease 1.42 1.34–1.50 135.89 1.39 1.31–1.47 121.19
Prior PCI 0.70 0.67–0.74 162.68 0.72 0.68–0.76 144.66
Diabetes
Insulin diabetes vs. no diabetes 1.32 1.23–1.42 58.41 1.37 1.28–1.47 76.44
Noninsulin diabetes vs. no diabetes 1.16 1.09–1.22 23.58 1.18 1.12–1.26 32.89
GFR, ml/min/1.73 m2y 0.90 0.90–0.91 673.43 0.90 0.90–0.91 679.80
Renal failure, GFR<30, ml/min/1.73 m2 or dialysis 1.55 1.42–1.68 104.48 1.55 1.42–1.68 105.65
EFy 0.90 0.89–0.91 377.63 0.89 0.88–0.90 543.86
Cardiogenic shock and PCI statusx 3,666.71
Sustained shock and salvage 141.36 119.74–166.87 3,420.73 164.31 139.30–193.81 5,131.47
Sustained shock or salvage 54.84 48.99–61.38 4,842.11 60.73 54.27–67.95 3,697.87
Transient shock but not salvage 31.68 28.25–35.53 3,488.06 34.33 30.64–38.48 1449.09
Emergency PCI without shock/salvage 7.57 6.80–8.43 1,365.59 7.99 7.18–8.89 442.23
Urgent PCI without shock/salvage 2.71 2.47–2.98 426.39 2.76 2.51–3.04 207.07
Heart failure NYHA class within 2 weeksx
IV 1.71 1.58–1.85 186.70 1.76 1.63–1.90 207.07
I/II/III 1.20 1.12–1.29 23.29 1.21 1.12–1.30 25.25
Cardiac arrest within 24 h 3.75 3.51–4.00 1,553.24 3.66 3.43–3.91 1,510.24
At least 1 previously treated lesion within 1 month
with in-stent thrombosis
2.11 1.71–2.59 49.75
Highest risk lesion: segment category
pLAD vs. other 1.33 1.26–1.40 101.60
Left main vs. other 2.06 1.85–2.28 178.36
Number of diseased vessels: 2, 3 vs. 0, 1 1.53 1.46–1.61 294.84
Chronic total occlusion 1.55 1.40–1.71 69.99
*Per 10-U increase. yPer 5-U increase. zcardiogenic shock & PCI status. xVersus no heart failure within 2 weeks.
cath¼ catheterization; CI¼ conﬁdence interval; EF¼ ejection fraction; NCDR¼ National Cardiovascular Data Registry; OR¼ odds ratio; pLAD ¼
proximal left anterior descending; other abbreviations as in Tables 1 and 2.
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795was similar across most PCI centers (median: 2.6% of PCI
cases, interquartile range [IQR]: 1.7% to 3.7%).
Observed in-hospital mortality increased incrementally
with increasing clinical acuity (Table 2). In the absence of
cardiogenic shock, the risk of in-hospital mortality for
elective, urgent, and emergent cases was 0.2%, 0.6%, and
2.3%, respectively. In the presence of transient shock but
not salvage status, the risk of in-hospital mortality was
15.1%; with sustained shock or salvage, the risk was 33.8%;
and, with sustained shock and salvage, the risk was 65.9%.
After adjusting for patient demographics, comorbidities,and angiographic characteristics, clinical acuity retained
the strongest association with in-hospital mortality
(Table 3).
Updated CathPCI Registry mortality model performance. The
full, pre-cath, and bedside risk adjustment models are
provided in Tables 3 and 4. Compared with CathPCI
Registry DCF v3 models, other variables new to the DCF v4
models included the treatment of chronic total occlusions
(odds ratio [OR]: 1.59, 95% conﬁdence interval [CI]: 1.42
to 1.78) and stent thrombosis (OR: 2.11, 95% CI: 1.71 to
2.59). Using the full CathPCI Registry DCF v4 model, the
Table 4. NCDR CathPCI Registry Bedside Risk Scoring System
Scoring Response Categories Total Points
Risk of
In-Patient
Mortality, %
STEMI No Yes 0 0.0
0 6 5 0.0
10 0.1
Age <60 60–70 70–80 80 15 0.1
0 4 9 15 20 0.2
25 0.3
BMI <20 20–30 30–40 40 30 0.6
5 1 0 3 35 0.9
40 1.4
CVD No Yes 45 2.3
0 2 50 3.7
55 5.9
PAD No Yes 60 9.2
0 3 65 14.2
70 21.2
Chronic lung
disease
No Yes 75 30.4
0 3 80 41.5
85 53.6
Prior PCI No Yes 90 65.2
3 0 95 75.3
100 83.2
Diabetes mellitus No Noninsulin Insulin 105 88.9
0 2 3 110 92.9
115 95.5
GFR Renal failure 30–45 45–60 60–90 90 120 97.2
16 11 7 3 0 125 98.2
130 98.9
EF <30 30–40 40–50 50 135 99.3
9 4 2 0 139 99.5
Cardiogenic
shock/PCI
status
Sustained
shock and
salvage
Sustained
shock alone
or salvage
alone
Transient
shock
but not
salvage
Emergency
PCI without
shock/
salvage
Urgent PCI
without
shock/
salvage
Elective
PCI
without
shock/
salvage
54 43 37 22 11 0
NYHA class
within 2 weeks
NYHA class IV NYHA class <IV No HF
7 3 0
Cardiac arrest
within 24 h
No Yes
0 13
HF ¼ heart failure; other abbreviations as in Tables 1 to 3.
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796majority of patients (>95%) had a predicted mortality risk of
<5%, and only a small minority of patients (<1.5%) had
a predicted risk >20% (Fig. 2).
Each of the 3 models performed well in the overall vali-
dation sample (full model, C-index: 0.930; pre-cath model:
0.929; CathPCI Registry Risk Prediction Score: 0.925) and
within each of the pre-speciﬁed patient subgroups (Table 5).
The full model calibration plots are shown for low-risk
(<5% predicted risk) and high-risk (>20% predicted risk)
patients in Figure 3. The model was well calibrated
throughout the range of risk, with slight underestimation ofrisk among those with a predicted risk of 20% to 50% and
slight overestimation among the small minority of patients
with a predicted risk >50%.
Discussion
In contemporary practice, less than one-half of all PCI
procedures (45%) are considered elective, and a large
proportion of procedures (18%) are performed in the setting
of clinical instability. Cardiogenic shock carries a signiﬁcant
incidence of in-hospital mortality (11), and early
Figure 2. Distribution of Predicted Risk Across the CathPCI Registry
Validation Sample
Demonstrates the distribution of predicted risk of in-hospital mortality in the
validation sample using the full CathPCI Registry risk prediction model.
Abbreviations as in Figure 1.
Figure 3. Calibration of the Full Model Among Low (<5% Predicted Risk)
and High-Risk (>20% Predicted Risk) Patients in the Validation Sample
Demonstrates observed versus predicted mortality estimates (and the 95%
conﬁdence interval) for equally sized risk groups of (A) low- and (B) high-risk
patients, based on the full-risk prediction model evaluated in the validation
sample. The Hosmer-Lemeshow goodness-of-ﬁt test statistic for the full model
in the validation sample was <0.05.
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797revascularization in this setting has been shown to improve
both short- and long-term survival (12–14). In this analysis,
we have shown that both the duration of shock and its
association with cardiac arrest are important features in the
estimation of predicted survival following PCI. Discrimi-
nation of risk within the rubric of “cardiogenic shock” is
possible in the setting of a national cardiovascular procedural
registry, and with the inclusion of more detailed data char-
acterizing clinical acuity, accurate risk prediction is possible
throughout the spectrum of procedural risk.
Although a minority of patients (<3%) present with
either cardiogenic shock or salvage status, clinical acuity
remains the strongest predictor of PCI procedural mortality
in contemporary practice. As in the SHOCK (Should We
Emergently Revascularize Occluded Coronaries for Car-
diogenic Shock) trial (12), early mortality following PCI
in the setting of cardiogenic shock remains high inTable 5. NCDR Model Discrimination in the Validation Sample, C-Indexes
Sample, n
Full
Model
Pre-Cath
Model Only
NCDR Risk
Score
Development 724,883 0.931 0.929 0.925
Validation 483,254 0.930 0.928 0.925
Subgroups, in validation
STEMI 77,298 0.900 0.896 0.893
Without STEMI 405,956 0.901 0.898 0.894
Women 157,427 0.919 0.916 0.911
Men 325,827 0.935 0.933 0.931
Age >70 yrs 159,531 0.905 0.903 0.898
Age 70 yrs 323,723 0.938 0.935 0.933
Diabetes mellitus 173,356 0.930 0.928 0.922
No diabetes mellitus 309,898 0.930 0.928 0.926
Abbreviations as in Tables 2 and 3.contemporary practice. Nevertheless, despite the compara-
tively high mortality rates associated with cardiogenic shock,
PCI in this setting is not a futile exercise. Among the sickest
PCI patients with both sustained shock and a recent cardiac
arrest, nearly 35% survived to hospital discharge. Without
recent cardiac arrest, the probability of survival was consid-
erably higher, with nearly 65% and 85% hospital survival
among patients who underwent PCI in the setting of sus-
tained or transient shock, respectively.
The probability of survival for patients with cardiogenic
shock is higher in contemporary practice than was previ-
ously reported by the SHOCK trial (12); however, direct
comparison of these results to those previously reported is
challenging. Although the deﬁnition of cardiogenic shock is
nearly identical between the SHOCK trial and that used for
the current CathPCI Registry DCF, the SHOCK trial
analysis did not stratify patients according to persistence
of shock; rather, patients were randomized within 36 h of
an index myocardial infarction and no more than 12 h after
the diagnosis of shock (12). In that setting, 30-day survival
among the revascularization cohort was 53.3%, which
was considerably lower than that observed in contempo-
rary practicedeven among patients with sustained shock.
Brennan et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 8 , 2 0 1 3
Enhanced Mortality Risk Prediction A U G U S T 2 0 1 3 : 7 9 0 – 9
798Consistent with the SHOCK trial results, survival to hospital
discharge among post–myocardial infarction cardiogenic
shock or salvage patients treated in the CathPCI Registry
between 1998 and 2002 was low (40.6%) (15). Nonetheless,
the deﬁnition of cardiogenic shock in the previous American
College of Cardiology-NCDR analysis was considerably
more restrictive than in DCF v4 (systolic blood pressure<80
mm Hg, cardiac index <1.8 l/min/m2, and pulmonary
capillary wedge pressure>20 mmHg in the setting of clinical
hypoperfusion, or the requirement for mechanical or phar-
macologic support to maintain a systolic blood pressure >80
mm Hg or cardiac index >1.8 l/min/m2). Although the
apparent contemporary improvements in the survival of
patients with cardiogenic shock may be due to less restrictive
data deﬁnitions or more restrictive patient selection, it is
perhaps as likely that greater access to early revascularization
and advances in both pharmacologic and mechanical treat-
ment modalities are responsible for recent improvements in
patient outcomes (11).
Despite a reasonable probability of survival following PCI
for even the most acute patients, considerable trepidation
persists among some in the interventional cardiology com-
munity that treatment of these patients may adversely affect
publicly reported clinical outcomes. On the contrary, in this
analysis, we have shown that the current CathPCI Registry
mortality risk prediction models are well calibrated through-
out the range of risk, with a slight overestimation of risk
among the minority of patients with the highest predicted risk.
In addition to further stratiﬁcation of clinical stability, the
updated models have included an indicator for interventions
involving chronic total occlusions, building on previous
work that has suggested an increased procedural risk of
mortality as compared with non–chronic total occlusion
interventionsdespecially when the intervention is unsuc-
cessful (16). Although the updated models perform well
across hospitals, a quantitative appraisal of the actual impact
of “extreme risk” cases on risk-adjusted hospital and provider
outcomes remains the focus of ongoing research efforts.
Direct comparison of the current CathPCI Registry DCF
v4 mortality models with previously published CathPCI
Registry (DCF v3) models (2) is not possible. Even though
calibration of the current models is similar to those previously
developed (C-statistic: 0.930 vs. 0.924), the application of the
2 bedside risk prediction tools to a common clinical scenario
may be instructive. In the case of a previously healthy patient
64 years of age who presents emergently to the cardiac cath-
eterization lab with an anterior STEMI associated with
transient cardiogenic shock and an EF of 45% without cardiac
arrest, the patient’s probability of in-hospital mortality
following PCI is estimated at roughly 2% (43 points) using
the current v4 CathPCI Registry model. By comparison,
using the v3 CathPCI Registry model, this same patient
would have had an estimated probability of in-hospital
mortality of roughly 10% (49 points). As demonstrated here,although population-level risk discrimination is similar for
each of these models, the difference in actual risk estimation is
apparent among certain high-risk patient populations.
Risk prediction models have multiple clinical applications,
including patient and family counseling, as a foundation for
quality assessment and improvement. As an adjunct to
patient counseling, the CathPCI Registry mortality models
have been incorporated as the backbone of the recently
presented Personalized Risk Information Services Manager,
or PRISM, consent process (3). In addition, both the
National Quality Forum (4) and the Leapfrog Group (5)
have endorsed the use of the CathPCI Registry model of
risk-adjusted in-hospital mortality following PCI as a quality
standard; the measure is used by multiple payers, including
Blue Cross Blue Shield, WellPoint, and UnitedHealthcare
Services for both quality improvement and recognition-
reward programs. Given their wide application, it is vital that
these models are reﬂective of both: 1) the most current
understanding of clinical characteristics associated with
PCI-related mortality; and 2) the most contemporary PCI
cohort available. The current CathPCI Registry mortality
models are responsive to both of these needs.
Study limitations. Despite its expanding role as the largest
clinical PCI registry in the United States, the CathPCI
Registry under-represents smaller volume practices. Even
though the NCDR has a Data Quality Program (which
includes an assessment for reasonableness and completeness
via the data quality report) and a data validation (audit)
program (17), the data remain susceptible to collection and
reporting biases and errors. Although variables indicating
procedural acuity have strict data deﬁnitions, the accuracy of
coding of these variables is particularly susceptible to center-
level variation. In addition, even though the current version
of the CathPCI Registry includes several important variables
that are associated with a high-risk for in-hospital mortality,
there may be other clinical characteristics (such as patient
frailty) (18) that are also prognostically important. Such
variables are difﬁcult to capture in the context of a quality
improvement registry, but may further reﬁne risk prediction.Conclusions
Despite apparent improvements in survival in the setting of
high-risk PCI, peri-procedural clinical instability remains
a powerful predictor of in-hospital mortality. With the
inclusion of indicators for high-risk PCI, the updated
CathPCI Registry DCF v4 mortality models perform well in
both low- and high-risk PCI patient populations.Acknowledgments
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